Sorry, you need to enable JavaScript to visit this website.

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.

Sign Up for AlertsDetails
Title
Grant Type
Focus Area
Country
Application Due Date
Education on the Appropriate Diagnosis and Treatment of Overactive Bladder or Neurogenic Bladder
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Internal Medicine Japan
Interventional Research Studies with Elranatamab
Release Date:
Review Process: Pfizer Internal
Research Oncology All
Research in Ulcerative Colitis (UC) 2024
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology Brazil, India, Mexico, Saudi Arabia, Taiwan, Turkey
Advances in the Management of Ulcerative Colitis (UC)
Release Date:
Review Process: Pfizer Internal
Education Inflammation & Immunology All
Research in Ulcerative Colitis (UC) 2024
Release Date:
Review Process: Expert Review Panel
Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology USA
BCMA-Directed Bispecific Antibody Treatment in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Translation: Japanese (link)
Education Oncology Japan
Research on MBL producing Enterobacterales and/or Stenotrophomonas maltophilia
Release Date:
Review Process: Pfizer Internal
Research Hospital Austria, Brazil, China, France, Germany, Greece, India, Italy, Mexico, Saudi Arabia, Spain, Taiwan, Turkey, United Kingdom
Increase Awareness & Understanding of Emerging Hemophilia Treatment Options (Global excluding United States)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease All
Optimal management of patients with prostate cancer receiving androgen deprivation therapy (ADT)
Release Date:
Partner: Sumitomo Pharma
Review Process: Pfizer Internal
Education Oncology USA
Improving the Outpatient Management of Emergency Department Patients with Venous Thromboembolism (VTE)
Release Date:
Partner: American College of Emergency Physicians (ACEP)
Review Process: Expert Review Panel
Quality Improvement Internal Medicine USA
HER2 Expression in Urothelial Carcinoma (UC)
Release Date:
Review Process: Pfizer Internal
Education Oncology All
Title
Grant Type
Focus Area
Country
Application Due Date
Education for Improvement of Early Detection and Appropriate Anticoagulant Therapy for Atrial Fibrillation
Release Date:
Review Process: Pfizer Internal
Education Internal Medicine Japan
Education and Support for Patients with Locally-Advanced or Metastatic Bladder Cancer
Release Date:
Partner: Merck KGaA, Darmstadt, Germany and EMD Serono
Review Process: Pfizer Internal
Education Oncology USA
Pre-clinical & Translational Research in Multiple Myeloma
Release Date:
Review Process: Pfizer Internal
Research Oncology Canada, USA
Management of Patients with BRAF-mutant metastatic colorectal cancer
Release Date:
Review Process: Pfizer Internal
Education Oncology Canada, USA
Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease
Release Date:
Review Process: Pfizer Internal
Quality Improvement Rare Disease All
Promotion of Smoking Cessation Treatment in General Practice
Release Date:
Review Process: Pfizer Internal
Education Internal Medicine Japan
2021 Growth Hormone Research (All countries except for the United States)
Release Date:
Review Process: Pfizer Internal
Research Rare Disease All
Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain
Release Date:
Partner: Lilly
Review Process: Pfizer Internal
Education Internal Medicine All
NSCLC Therapy Management for Optimal Outcomes
Release Date:
Review Process: Pfizer Internal
Quality Improvement Oncology Andorra, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, USA, United Kingdom
Clinical Research Capability Development
Release Date:
Review Process: Pfizer Internal
Education Internal Medicine China
Educational Program to Increase Awareness and Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Release Date:
Review Process: Pfizer Internal
Education Rare Disease China
Advances in Moderate-to-Severe Atopic Dermatitis for Dermatologists and Allergists
Release Date:
Review Process: Pfizer Internal
Education Inflammation & Immunology USA